|
|
Volumn 243, Issue 7, 2005, Pages 701-705
|
|
A prospective, open-label, dose-escalating study of low molecular weight heparin during repeat vitrectomy for PVR and severe diabetic retinopathy
a
a,e
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ENOXAPARIN;
INFUSION FLUID;
ADULT;
ARTICLE;
CLINICAL ARTICLE;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DIABETIC RETINOPATHY;
DISEASE SEVERITY;
DOSE RESPONSE;
DRUG DOSE REGIMEN;
DRUG MEGADOSE;
DRUG TOLERABILITY;
EYE TOXICITY;
HUMAN;
HYPHEMA;
INTRAOCULAR HEMORRHAGE;
INTRAOPERATIVE PERIOD;
LOW DRUG DOSE;
MAXIMUM TOLERATED DOSE;
OPEN STUDY;
PHASE 1 CLINICAL TRIAL;
PRIORITY JOURNAL;
PROSPECTIVE STUDY;
RANK SUM TEST;
REOPERATION;
RETINA DETACHMENT;
SYSTEMIC DISEASE;
VITRECTOMY;
VITREORETINOPATHY;
VITREOUS HEMORRHAGE;
DIABETIC RETINOPATHY;
ENOXAPARIN;
FEMALE;
FIBRIN;
FIBRINOLYTIC AGENTS;
HUMANS;
HYPHEMA;
INFUSION PUMPS;
INTRAOPERATIVE COMPLICATIONS;
MALE;
MAXIMUM TOLERATED DOSE;
MIDDLE AGED;
PROSPECTIVE STUDIES;
REOPERATION;
VITRECTOMY;
VITREORETINOPATHY, PROLIFERATIVE;
VITREOUS HEMORRHAGE;
|
|
EID: 22144455702
PISSN: 0721832X
EISSN: None
Source Type: Journal
DOI: 10.1007/s00417-004-0912-0 Document Type: Article |
|
Times cited : (7)
|
|
References (9)
|
